DTL抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P09474(DTL Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

DTL antibodies target the DTL (Denticleless E3 Ubiquitin Protein Ligase Homolog) protein, a key regulatory component in cell cycle progression and DNA damage response. Also known as CDT2 or L2DTL, DTL participates in the CRL4^(CDT2) E3 ubiquitin ligase complex, which governs the degradation of cell cycle inhibitors like p21 and SET8. ensuring proper S-phase progression and genomic stability. Its role in DNA replication licensing and repair has linked DTL dysregulation to oncogenesis, making it a potential biomarker and therapeutic target in cancers such as breast, lung, and colorectal carcinomas.

Research on DTL antibodies has expanded due to their utility in studying DNA damage mechanisms, replication stress, and tumorigenesis. These antibodies enable detection of DTL expression levels in tissues, aiding cancer prognosis assessments. Additionally, they facilitate functional studies using techniques like immunohistochemistry, Western blotting, and immunofluorescence. Recent investigations explore DTL's interaction with viral proteins and its involvement in chromatin remodeling, broadening its relevance in virology and epigenetics. While clinical applications remain exploratory, DTL antibodies are pivotal tools for unraveling cell cycle control networks and developing targeted anticancer strategies.